<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01749111</url>
  </required_header>
  <id_info>
    <org_study_id>GEDECH-2012</org_study_id>
    <nct_id>NCT01749111</nct_id>
  </id_info>
  <brief_title>Comparison Between Cyclophosphamide and Combination of Methotrexate + Calcineurin Inhibitor for GVHD Prophylaxis</brief_title>
  <acronym>CICLODECH</acronym>
  <official_title>Randomized Study to Compare Post Bone Marrow Transplant Cyclophosphamide With the Combination of Methotrexate Plus Calcineurin Inhibitor for Graft Versus Host Disease Prophylaxis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital Israelita Albert Einstein</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital Israelita Albert Einstein</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether cyclophosphamide post bone marrow
      transplant increases the rate of patients alive, in remission and without immunosuppression,
      one year after transplant, when compared with the combination of methotrexate and calcineurin
      inhibitor
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      We propose a study in which 150 patients will receive graft versus host disease prophylaxis
      with cyclophosphamide 50 mg/kg on day +3 and day +4 after bone marrow transplantation, and
      150 patients will receive the usual combination of methotrexate and calcineurin inhibitor.
      The study was designed to last for 4 years. The primary endpoint is the rate of patients
      alive, in remission and without immunosuppression, one year after transplant. The assignment
      for each arm of the study will be done through simple randomization.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Lack of accrual
  </why_stopped>
  <start_date>December 2012</start_date>
  <completion_date type="Actual">August 2016</completion_date>
  <primary_completion_date type="Actual">August 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The rate of patients alive, in remission and without immunosuppression, one year after bone marrow transplantation.</measure>
    <time_frame>one year</time_frame>
    <description>The rate of patients alive, in remission and without immunosuppression, one year after bone marrow transplantation.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cumulative incidence of chronic graft versus host disease, one year after bone marrow transplantation</measure>
    <time_frame>one year</time_frame>
    <description>Cumulative incidence of chronic graft versus host disease, one year after bone marrow transplantation</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Cumulative incidence of disease relapse, one year after bone marrow transplantation</measure>
    <time_frame>one year</time_frame>
    <description>Cumulative incidence of disease relapse, one year after bone marrow transplantation</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">3</enrollment>
  <condition>Acute Myelogenous Leukemia</condition>
  <condition>Acute Lymphoid Leukemia</condition>
  <condition>Myeloproliferative Disease</condition>
  <condition>Myelodysplastic Syndrome</condition>
  <condition>Chronic Myeloid Leukemia</condition>
  <condition>Chronic Myelomonocytic Leukemia</condition>
  <arm_group>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Graft versus host disease prophylaxis will be done with cyclophosphamide 50 mg/kg on day +3 and day +4</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>In this arm, patients will receive a combination of methotrexate and a calcineurin inhibitor as graft versus host disease prophylaxis</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ARM A Cyclophosphamide</intervention_name>
    <description>Cyclophosphamide 50 mg/kg on day+3 and day+4 after bone marrow transplantation</description>
    <arm_group_label>Arm A</arm_group_label>
    <other_name>Cyclophosphamide</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ARM B Calcineurin inhibitor and methotrexate</intervention_name>
    <description>Graft versus host disease prophylaxis will be done with the combination of a calcineurin inhibitor (either tacrolimus or cyclosporine) and methotrexate</description>
    <arm_group_label>Arm B</arm_group_label>
    <other_name>Calcineurin inhibitor and methotrexate</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Man or woman 18 to 60 years of age.

          -  The patient should have a HLA matched donor

          -  The patient must need a bone marrow transplant for a malignant disease (Acute
             leukemia, myelodysplastic syndrome, myeloproliferative disease or
             myelodysplastic/myeloproliferative disease)

          -  Patients want to participate in the study, and able to give informed consent.

        Exclusion Criteria:

          -  Previous auto o allogeneic hematopoietic stem cell transplant

          -  Performance Status &gt;2 (ECOG).

          -  Pregnancy

          -  HIV positive

          -  Active Infection

          -  Cardiac disease with ejection fraction &lt; 45%

          -  Lung disease with FEV1, FVC ou DLCO &lt;50% of predicted values.

          -  Renal Insufficiency with creatinine clearance &lt; 60 ml/minute.

          -  Liver disease with bilirubin levels &gt; twice the reference value or ALT or AST &gt; three
             times the normal reference.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paulo V Campregher, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Israelita Albert Einstein</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Instituto Israelita de Ensino e Pesquisa Albert Einstein 's (IIEP)</name>
      <address>
        <city>São Paulo</city>
        <zip>05652-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <reference>
    <citation>Luznik L, Bolaños-Meade J, Zahurak M, Chen AR, Smith BD, Brodsky R, Huff CA, Borrello I, Matsui W, Powell JD, Kasamon Y, Goodman SN, Hess A, Levitsky HI, Ambinder RF, Jones RJ, Fuchs EJ. High-dose cyclophosphamide as single-agent, short-course prophylaxis of graft-versus-host disease. Blood. 2010 Apr 22;115(16):3224-30. doi: 10.1182/blood-2009-11-251595. Epub 2010 Feb 2.</citation>
    <PMID>20124511</PMID>
  </reference>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 11, 2012</study_first_submitted>
  <study_first_submitted_qc>December 12, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 13, 2012</study_first_posted>
  <last_update_submitted>March 2, 2017</last_update_submitted>
  <last_update_submitted_qc>March 2, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 3, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hospital Israelita Albert Einstein</investigator_affiliation>
    <investigator_full_name>Paulo Vidal Campregher</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>bone marrow transplantation</keyword>
  <keyword>graft versus host disease</keyword>
  <keyword>Acute myelogenous leukemia</keyword>
  <keyword>Acute lymphoid leukemia</keyword>
  <keyword>Myeloproliferative disease</keyword>
  <keyword>Myelodysplastic syndrome</keyword>
  <keyword>Chronic myeloid leukemia</keyword>
  <keyword>chronic myelomonocytic leukemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Graft vs Host Disease</mesh_term>
    <mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
    <mesh_term>Leukemia, Myelomonocytic, Acute</mesh_term>
    <mesh_term>Leukemia, Myelomonocytic, Chronic</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Leukemia, Myelomonocytic, Juvenile</mesh_term>
    <mesh_term>Myeloproliferative Disorders</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Calcineurin Inhibitors</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

